Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CUE

+ Watchlist+ Portfolio

Cue Biopharma, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.83
52-Week Range
$2.83 – $45.50
Market Cap
$39.79M
P/E (TTM)
—
EPS (TTM)
-27.80
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.96
PEG Ratio
—
Return on Equity
-800.39%
Return on Assets
-174.18%
Gross Margin
55.58%
Operating Margin
-386.69%
Profit Margin
0.00%
Current Ratio
3.38
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-76.02M
Revenue Growth
-93.90%
Earnings Growth
—
Enterprise Value
$-18.19M

Market Snapshot

About

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively modulate disease-relevant T cells. Headquartered in Boston, Massachusetts, the company's Immuno-STAT platform is designed to harness the body's immune system to fight cancer and autoimmune diseases. Cue Biopharma's lead programs target various cancers including HPV-driven malignancies and other solid tumors. The company's approach aims to deliver more targeted immunotherapy with improved efficacy and reduced side effects compared to traditional treatments.